Glioblastoma Exosome Research Solution

Exosomes isolated from blood and cerebrospinal fluid are cargo containers used by eukaryotic cells to exchange bioactive substances such as proteins, lipids, DNA, messenger RNA (mRNA), and non-coding RNAs. Exosomes can protect these biomolecules from degradation by nucleases and proteases. As one of the important members of the extracellular vesicles (EVs) family, exosomes participate in cell-cell communication, angiogenesis, tumor growth, and so on. Exosomes not only present a new method to detect cancer biomarkers but may also provide potential targets for cancer therapeutic interventions. In addition, exosomes have great potential in cancer therapy because they can serve as carriers for anticancer drug delivery.

Exosomes and glioblastoma (GBM)

Brain tumors are one of the most aggressive types of cancer. Among them, glioblastoma (GBM) has the worst prognosis. Recently, researchers have recognized the importance of exosomes in the development of GBM. Previous studies have shown that GBM cells release large amounts of exosomes and that the cargo of these exosomes allows them to promote GBM cell invasion and migration, stimulate the malignant transformation of previously normal cells, induce resistance to chemotherapy, increase immune tolerance towards GBM, and enhance GBM vascular supply. In particular, exosomal miRNAs and proteins have been reported to play a critical role in the pathogenesis and progression of gliomas. Exosomes are rapidly proving their value not only as non-invasive diagnostic and prognostic biomarkers, but also as therapeutic tools specifically targeting GBM cells. However, further research is needed to promote the use of exosomes in the diagnosis, prognosis, and treatment of GBM.

Fig. 1 The roles of exosomes in glioma's development. (Wu, Xiaoben, et al., 2021)

Pancreatic cancer exosome research solution at Creative Proteomics

Exosomes play a vital role in glioma tumor biology, immune responses, and the tumor microenvironment (TME) and can act as biomarkers for glioma diagnosis. Since exosomes are specific to their parental cells, isolating them will allow a deeper understanding of the pathogenesis of GBM. Creative Proteomics offers a reliable, rapid, cost-effective one-stop solution for exosome research in a wide range of cancers, including glioma, based on a highly stable, reproducible, and sensitive system for isolation, characterization, identification, and quantitative analysis. Specifically, we provide the following services, including but not limited to:

• Experimental design
• Cell culture and exosome isolation
• Labeling and purification of exosomes
• Identification of exosomes
• Exosome stability testing
• In vivo and in vitro detection of anticancer effects of exosomes
• Mass spectrometry (MS)-based exosome proteomics, metabolomics, and lipidomics

Our service support

• Exosomes as diagnostic and prognostic biomarkers for glioma
• Exosomes as therapeutic agents for glioma
• The regulation of exosomes in Glioma TME
• To identify the specific miRNA and protein content of exosomes and their mechanism of action in glioma

As a reliable partner for pharmaceutical companies, research institutions, and government agencies, Creative Proteomics can provide you with a wide range of exosome-related services to accelerate your cancer research progress. We appreciate your interest in our services. Let us know what you are trying to achieve and our team of experts will be in touch with you within one business day to discuss your needs. Contact us right now!

References

1. Wu, Xiaoben, et al. "The roles of exosomes as future therapeutic agents and diagnostic tools for glioma." Frontiers in Oncology 11 (2021).
2. Ghaemmaghami, Amir B., et al. "Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis." Cell Communication and Signaling 18.1 (2020): 1-19.

* For Research Use Only. Not for use in diagnostic procedures.